An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

被引：27

作者：

Alexis, JB

Martinez, AE

Lutzky, J

机构：

[1] Mt Sinai Med Ctr, Dept Pathol & Lab Med, Miami, FL 33140 USA

[2] Miami Univ, Sch Med, Miami, FL 33140 USA

[3] Mt Sinai Med Ctr, Comprehens Canc Ctr, Miami, FL 33140 USA

[4] Mt Sinai Med Ctr, Arkadi M Rywilin MD Dept Pathol & Lab Med, Miami, FL 33140 USA

来源：

MELANOMA RESEARCH | 2005年 / 15卷 / 04期

关键词：

chemotherapy; c-kit; immunohistochemistry; melanoma;

D O I：

10.1097/00008390-200508000-00008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1 + or stronger labelling for CD-117 (up to a maximum of 4 +). Three patients with neoplasms showing 4 + staining were selected for imatinib therapy. None responded. c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.

引用

收藏

页码：283 / 285

页数：3

相关论文

共 12 条

[1] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[2]

DiPaola RS, 1997, CANCER GENE THER, V4, P176

[3] CD 117 (KIT): A diverse protein with selective applications in surgical pathology [J].

Gibson, PC ;

Cooper, K .

ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (01) :65-69

[4] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor [J].

Heinrich, MC ;

Griffith, DJ ;

Druker, BJ ;

Wait, CL ;

Ott, KA ;

Zigler, AJ .

BLOOD, 2000, 96 (03) :925-932

[5] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].

Heinrich, MC ;

Corless, CL ;

Demetri, GD ;

Blanke, CD ;

von Mehren, M ;

Joensuu, H ;

McGreevey, LS ;

Chen, CJ ;

Van den Abbeele, AD ;

Druker, BJ ;

Kiese, B ;

Eisenberg, B ;

Roberts, PJ ;

Singer, S ;

Fletcher, CDM ;

Silberman, S ;

Dimitrijevic, S ;

Fletcher, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349

[6] Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis [J].

Huang, S ;

Jean, D ;

Luca, M ;

Tainsky, MA ;

Bar-Eli, M .

EMBO JOURNAL, 1998, 17 (15) :4358-4369

[7]

Huang SY, 1996, ONCOGENE, V13, P2339

[8] PROGRESSION OF HUMAN CUTANEOUS MELANOMA IS ASSOCIATED WITH LOSS OF EXPRESSION OF C-KIT PROTOONCOGENE RECEPTOR [J].

NATALI, PG ;

NICOTRA, MR ;

WINKLER, AB ;

CAVALIERE, R ;

BIGOTTI, A ;

ULLRICH, A .

INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (02) :197-201

[9] c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi [J].

Ohashi, A ;

Funasaka, Y ;

Ueda, M ;

Ichihashi, M .

MELANOMA RESEARCH, 1996, 6 (01) :25-30

[10] Drug therapy: Imatinib mesylate - A new oral targeted therapy. [J].

Savage, DG ;

Antman, KH .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :683-693